Omnicell (NASDAQ:OMCL) Stock Crosses Above 200-Day Moving Average – Should You Sell?

Omnicell, Inc. (NASDAQ:OMCL)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $39.55 and traded as high as $44.96. Omnicell shares last traded at $44.50, with a volume of 259,977 shares changing hands.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Benchmark reissued a “buy” rating and set a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. JPMorgan Chase & Co. increased their price objective on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Bank of America restated a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Finally, Barclays upped their price target on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus price target of $52.00.

Omnicell Trading Down 2.9 %

The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -110.77, a P/E/G ratio of 34.96 and a beta of 0.78. The company has a 50 day simple moving average of $45.60 and a 200-day simple moving average of $39.75.

Insider Activity at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the sale, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

Several large investors have recently modified their holdings of OMCL. Pacer Advisors Inc. grew its holdings in Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after buying an additional 508,789 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Omnicell by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after purchasing an additional 3,570 shares during the period. Victory Capital Management Inc. raised its position in shares of Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after buying an additional 1,138,921 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its position in Omnicell by 27.1% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after buying an additional 243,353 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after acquiring an additional 2,877 shares during the period. 97.70% of the stock is owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.